Introduction
============

Breast cancer is the most frequent malignancy and the second most frequent cause of cancer related death in women [@B1]. Inflammatory breast cancer (IBC), a locally advanced neoplasm, accounts for 1% to 2% of all invasive breast cancers [@B2]. Despite its rarity, IBC contributes to a disproportionate number of breast cancer specific mortality [@B3]. Due to tumor infiltration of the dermal lymphatics, the patients develop rapid onset of characteristic skin changes from the time of confirmed diagnosis [@B4]. Thus, it is crucial to make an accurate diagnosis and start rapid approach to treatment for this fatal malignancy.

By far, management of IBC is based on multimodality therapy which includes surgery, chemotherapy and radiation therapy [@B5], [@B6]. Under this circumstance, IBC patients have markedly poorer prognosis compared with non-inflammatory breast cancer, with under 55% of 5-year overall survival rate [@B7]. This disappointing prognostic data mainly attributes to high risk of distant metastasis and locoregional recurrence [@B8]. Surprisingly, 85% of IBC patients had regional lymph node invasion, and over 30% present with distant metastasis at the time of diagnosis [@B9]. Bone is a common metastatic organ for IBC, as well as visceral sites including lung and liver [@B10]. Previous studies suggested the prognostic difference between patients with bone metastasis and visceral metastasis [@B11], [@B12]. Also, IBC patients have a high risk of developing brain metastasis, which usually portends a frustrating prognosis with a median survival less than six months [@B13].

However, the metastatic pattern of IBC still needs further investigation. And the prognostic ending of diverse metastatic lesions needs to be elaborated more clearly. Therefore, it would be vital to illustrate the metastatic distribution for better clinical decision. In the present cohort study, we aimed to explore metastatic profiles of IBC, by reviewing data from the SEER database. And we also intended to elucidate the clinical and prognostic characteristics among different metastatic sites.

Methods
=======

Cohort population
-----------------

A retrospective cohort research was performed by using data from the Surveillance, Epidemiology and End Results (SEER) national database. The SEER\*Stat software (Version 8.4, National Cancer Institute, Washington DC, USA) was used to access the database and a data-use agreement was signed for this study.

Patients were enrolled in this study according to the following inclusion and exclusion criteria. Inclusion criteria: (1) Patients were diagnosed with inflammatory breast cancer; (2) Breast cancer was the first primary malignancy. Exclusion criteria: (1) Metastatic status was unknown; (2) Follow-up data was missing; (3) Information about molecular subtype was unknown. Patients diagnosed with IBC between 2010 and 2014 were studied as the training cohort, and IBC cases between 2015 and 2016 were assigned to the validation cohort. The detailed procedure of cohort selection was outlined (Fig. [1](#F1){ref-type="fig"}).

In this study, we intended to identify distant metastatic pattern of inflammatory breast cancer. And the SEER database contained metastatic information including bone, brain, liver, lung, and distant lymph nodes (DL), which could basically cover extensive metastatic sites of IBC.

Statistical analysis
--------------------

Patients\' demographic and clinical characteristics were summarized by descriptive statistics. Chi-square tests were applied to compare metastatic distribution among different molecular subtypes. Frequency distribution among different metastatic sites was analyzed by odds ratio calculation. Overall survival (OS) and cancer-specific survival (CSS) among different metastatic organs were analyzed by Kaplan-Meier methods and log-rank tests. Independent prognostic risk factors were further assessed by multivariate Cox proportional hazards models. All tests were two-sided and P\<0.05 indicated statistical significance. All statistical analyses were conducted by GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) and SPSS 22.0 (SPSS Inc. Chicago, IL, USA).

Results
=======

Patient characteristics
-----------------------

In total, we selected 635 patients with the diagnosis of inflammatory breast cancer in the training cohort and 242 patients in the validation cohort. In the training cohort, 224 cases (35.3%) were HR-positive/HER2-negative, 133 cases (20.9%) were HR-positive/HER2-positive, 109 cases (17.2%) were HR-negative/HER2-positive, and 169 cases (26.6%) were triple negative breast cancer (TNBC). The baseline clinical characteristics were illustrated in Table [1](#T1){ref-type="table"}. And in the validation cohort, 74 cases (30.6%) were HR-positive/HER2-negative, 52 cases (21.5%) were HR-positive/HER2-positive, 59 cases (24.4%) were HR-negative/HER2-positive, and 57 cases (23.6%) were triple negative breast cancer (TNBC) ([Supplementary Table 1](#SM0){ref-type="supplementary-material"}).

Demographic and clinicopathological parameters including marital status, race, tumor size, and regional lymph node invasion showed significant differences between the metastatic group and non-metastatic group. Compared to non-metastatic group, metastatic group tended to have higher rate of unmarried status, lower incidence of white race, larger tumor size and higher frequency of regional lymph node invasion. As for therapies, metastatic patients received less surgery, chemotherapy or radiation therapy than non-metastatic patients.

Among 635 enrolled cases in the training cohort, 224 cases (35.3%) were reported with distant metastasis. According to the obtained information from SEER database, the five metastatic organs (bone, brain, liver, lung and DL) accounted for 93.8% (210/224) of all metastatic IBC patients. Bone and brain were the most and least common metastatic organs, accounting for 57.6% (129/224) and 6.3% (14/224), respectively. In the validation cohort, 80 cases (33.1%) had distant metastasis, and bone and brain were the most and least common metastatic organs, accounting for 60.0% (48/80) and 7.5% (6/80), respectively.

Metastatic pattern
------------------

Based on the molecular subtype, IBC were classified into HR+/HER2-, HR+/HER2+, HR-/HER2+ and TNBC for metastatic distribution comparison. It is clearly shown in the two cohorts that bone was the most frequent metastatic organ and brain was the least frequent of all subtypes of IBC, separately (Fig. [2](#F2){ref-type="fig"}, [Supplementary Fig. 1](#SM0){ref-type="supplementary-material"}). Notably, there were some differences in patterns of metastasis among different subtypes in the training cohort. Incidence rate of bone metastasis was highest in HR+/HER2- (26.3%) and lowest in TNBC (12.4%). And the rate of brain metastasis was lowest in HR+/HER2- (0%) and highest in HR-/HER2+ (6.4%). And different subtypes of IBC showed no significantly diverse intends to lung, liver, and DL metastasis. The similar trends were observed in the validation cohort that incidence rate of bone metastasis was highest in HR+/HER2- (25.7%) and rate of brain metastasis was highest in HR-/HER2+ (6.8%).

Combination of metastases
-------------------------

Many patients developed more than one metastatic site simultaneously or sequentially. We drew pie charts to illustrate proportions of each single metastasis and combined metastatic patterns among all subtypes of IBC (Fig. [3](#F3){ref-type="fig"}, [Supplementary Fig. 2](#SM0){ref-type="supplementary-material"}). It is shown that bone and DL were two leading lesions as a single metastatic site for IBC. As for combination of metastases, bi-site pattern (HR+/HER2-: 24.4%, HR+/HER2+: 20.8%, HR-/HER2+: 22.0%, TNBC: 32.1%) was dominantly higher than tri-site (HR+/HER2-: 11.0%, HR+/HER2+: 18.8%, HR-/HER2+: 4.9%, TNBC: 7.6%) and tetra-site pattern (HR+/HER2-: 3.7%, HR+/HER2+: 6.3%, HR-/HER2+: 7.3%, TNBC: 1.9%) in the training cohort. The results were further confirmed in the validation cohort.

For a better understanding of the interaction among these metastatic lesions, odds ratio of each possible combination between all five organs was compared (Fig. [4](#F4){ref-type="fig"}). Liver metastasis preferentially intended to co-metastasize with bone metastasis (OR: 11.135) and brain metastasis (OR: 6.632). Their metastatic combinations were far more common than any other co-metastasis with liver. Lung metastasis was also specially related to brain (OR: 8.132), bone (OR: 6.920) and DL metastasis (OR: 4.597).

Survival
--------

In this cohort research, 290 deaths (45.7%) were observed among 635 patients. We calculated 1-year OS and CSS for patients with different metastatic lesions (Table [2](#T2){ref-type="table"}). And there were extraordinarily large differences (P\<0.001) in 1-year OS and CSS between patients with or without metastasis in all five organs (OS: bone 67.4% vs 84.6%, lung 60.0% vs 83.9%, liver 45.3% vs 84.4%, brain 50.0% vs 81.8%, DL 60.5% vs 83.9%; CSS: bone 71.3% vs 87.2%, lung 65.3% vs 86.4%, liver 49.1% vs 87.1%, brain 50.0% vs 84.7%, DL 63.2% vs 86.8%). Kaplan-Meier curves were applied to analyze the survival data of CSS more intuitively in both cohorts (Fig. [5](#F5){ref-type="fig"}, [Supplementary Fig. 3](#SM0){ref-type="supplementary-material"}).

Moreover, multivariate Cox regression models were performed to identify whether metastatic status was an independent prognostic factor (Table [3](#T3){ref-type="table"}, [Supplementary Table 2](#SM0){ref-type="supplementary-material"}). After adjusting for molecular subtype, age, race, marital status, grade, tumor size, regional lymph node invasion and therapies, we found that different metastatic sites were all related to worse OS (bone: HR 1.989, 95%CI 1.487-2.660; lung: HR 1.929, 95%CI 1.395-2.667; liver HR 4.008, 95%CI 2.823-5.690; brain HR 2.707, 95%CI 1.341-5.465; DL HR 2.178, 95%CI 1.563-3.036), as well as worse CSS (bone: HR 2.081, 95%CI 1.527-2.838; lung: HR 1.970, 95%CI 1.395-2.780; liver HR 4.418, 95%CI 3.064-6.370; brain HR 3.213, 95%CI 1.583-6.519; DL HR 2.435, 95%CI 1.725-3.437). And in the validation cohort, all the different metastatic sites were identified as independent risk factors for unfavorable OS and CSS.

In addition, prognostic differences between different bi-site metastatic patterns were compared among the four solid organs (bone, lung, brain and liver) by Kaplan-Meier methods (Fig. [6](#F6){ref-type="fig"}). It is clearly shown that brain metastasis combined with lung or bone, and lung metastasis combined with liver ended up worse prognosis than the separated single metastasis. Interestingly, as for the combined metastasis of brain and liver, also lung and bone, bi-site metastasis resulted in no worse ending than the separated single metastasis.

Discussion
==========

Inflammatory breast cancer shows unfavorable prognosis mainly attributable to early distant metastasis [@B14], [@B15]. It is important to have a clear understanding of its metastatic pattern. In our research, the following three points were mainly elaborated: (1) Elucidating the distribution of single-organ metastases in IBC; (2) Clarifying the combined metastatic patterns and tendency of co-metastases; (3) Analyzing prognostic values of single-organ and bi-organ metastases. To our knowledge, this SEER-based research is the first comprehensive, large-cohort research focusing on the distal metastatic pattern of IBC and considering different molecular subtypes as separate entities. And we hope our results can be beneficial for treatment selection and clinical research.

As previous studies mentioned, the prevalence in breast cancer patients developing bone metastasis is extremely high. That is to say, bone is the most common metastatic lesion in both IBC and non-IBC patients [@B16], [@B17]. Consistent with the conventional views, we found that bone and brain were the most and least common metastatic organs for all subtypes of IBC, separately. Several differences existed among different molecular subtypes in bone and brain, but not in lung, liver or DL. Incidence rate of bone metastasis was highest in HR+/HER2-, followed by HR+/HER2+, HR-/HER2+ and lowest in TNBC.

And we also found that the rate of brain metastasis was highest in HR-/HER2+, followed by TNBC, HR-/HER2+ and lowest in HR+/HER2-. Previous articles showed that TNBC had a significantly lower rate of bone metastasis than HR+/HER2- tumors [@B18], and that HR-/HER2+ patients had a higher risk of brain metastasis than HR+/HER2- patients [@B19], [@B20]. These previous findings were supported by our research in IBC.

According to the baseline clinical characteristics, parameters including marital status, race, tumor size, and regional lymph node invasion showed significant differences between the metastatic group and non-metastatic group. Compared to non-metastatic group, metastatic group tended to have higher rate of unmarried status, lower incidence of white race, larger tumor size and higher frequency of regional lymph node invasion. As for therapies, metastatic patients received less surgery, chemotherapy or radiation therapy than non-metastatic patients. In consideration of these clinical parameters that could have influence on patient survival, we performed multivariate Cox regression models for further investigation. After adjusting for demographic, clinicopathological and therapeutic variables, we suggested that all single-organ metastases were independent risk factors for prognosis.

By far, previous studies have not focused on the combined metastatic patterns of IBC. Our findings showed that not any two metastatic organs were randomly combined for bi-site metastasis. For instance, liver metastasis had a preference for co-metastasizing with bone and brain. And lung was a common co-metastatic site for brain, bone and DL. Although the sequential information of co-metastatic organs was not provided by the SEER database, knowing the tendency of metastatic combinations would be beneficial for risk assessment and diagnostic screening in IBC patients with advanced stage. Additionally, we also analyzed the prognostic significance of different combinations with bi-organ metastases. However, not all bi-organ metastases had an unfavorable prognosis than the single-site metastases, which could be challenging for the conventional views. It could be partially explained that single-site metastasis may have already resulted in a fatal ending in some circumstances. And we hope further investigations could be conducted to better answer this phenomenon.

As far as we know, this cohort study is among the innovative work to summarize metastatic patterns of different molecular subtypes of IBC. As a retrospective research, several potential limitations need to be mentioned. First, since SEER database collected detailed information on distal metastatic site and molecular subtype from 2010, we only enrolled patients diagnosed with IBC between 2010 and 2016. Second, metastatic data extracted from the database is restricted to five organs (bone, lung, liver, brain and distant lymph node) and other distal sites are unclear. However, these five sites accounted for more than 90% of metastatic lesions and only a relatively small proportion of other sites may be ignored. Third, the metastatic information in this study was synchronous metastasis at the time of diagnosis, meaning that metachronous metastasis was not included. Briefly, on the basis of single-organ and bi-organ metastatic patterns, we recommend that the primary neoplasm and the first metastatic lesion could be taken into consideration for predictive prognostic model and optimal treatment choice.

In conclusion, in this SEER-based cohort study, we illustrated the metastatic patterns in different subtypes of IBC. Bone and brain were the most and least common metastatic organs for all subtypes of IBC, separately. Bi-organ metastasis occurred most frequently among all combined metastases. Several combinations, such as liver and bone, lung and brain, were preferential for bi-organ metastasis. And all single organ distal metastases were independent risk factors for prognostic prediction (adjusting for molecular subtype, therapy and other clinicopathological variables). Therefore, our results would provide more information for future study design and clinical decision.
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###### 

Baseline clinical characteristics of inflammatory breast cancer patients.

  Characteristics                    No metastasis   Metastasis   *P* value          
  ---------------------------------- --------------- ------------ ----------- ------ ---------
  **Subtype**                                                                        0.658
  HR+/HER2-                          142             34.5         82          36.6   
  HR+/HER2+                          85              20.7         48          21.4   
  HR-/HER2+                          68              16.5         41          18.3   
  TNBC                               116             28.2         53          23.7   
  **Age**                                                                            0.158
  \<50                               135             32.8         58          25.9   
  51-65                              204             49.6         127         56.7   
  ≥65                                72              17.5         39          17.4   
  **Marital status**                                                                 0.018
  Married                            206             50.1         87          38.8   
  Unmarried                          189             46.0         123         54.9   
  Unknown                            16              3.9          14          6.3    
  **Race**                                                                           0.007
  White                              336             81.8         160         71.4   
  Black                              46              11.2         44          19.6   
  Others\*                           29              7.1          20          8.9    
  **Grade**                                                                          0.308
  I                                  7               1.7          4           1.8    
  II                                 94              22.9         44          19.6   
  III                                211             51.3         105         46.9   
  IV                                 6               1.5          6           2.7    
  Unknown                            93              22.6         65          29.0   
  **Size (cm)**                                                                      0.027
  \<2.0                              39              9.5          20          8.9    
  2.0-4.9                            94              22.9         36          16.1   
  ≥5.0                               135             32.8         64          28.6   
  Unknown                            143             34.8         104         46.4   
  **Regional lymph node invasion**                                                   0.019
  N0                                 68              16.5         23          10.3   
  N1                                 186             45.3         97          43.3   
  N2                                 72              17.5         34          15.2   
  N3                                 76              18.5         60          26.8   
  NX                                 9               2.2          10          4.5    
  **Surgery**                                                                        \<0.001
  Yes                                320             77.9         77          34.4   
  No                                 91              22.1         147         65.6   
  **Chemotherapy**                                                                   \<0.001
  Yes                                371             90.3         178         79.5   
  No                                 40              9.7          46          20.5   
  **Radiation therapy**                                                              \<0.001
  Yes                                213             51.8         54          24.1   
  No                                 198             48.2         170         75.9   

\*Others include American Indian, AK Native, Asian, and Pacific Islander. HR: Hormone Receptor; TNBC: Triple-Negative Breast Cancer.

###### 

Survival analysis in diverse metastatic organs.

  Parameter                 1-year OS (%)   Univariate analysis   1-year CSS (%)   Univariate analysis            
  ------------------------- --------------- --------------------- ---------------- --------------------- -------- ---------
  **Bone**                                                                                                        
  No metastasis             84.6            22.612                \<0.001          87.2                  22.068   \<0.001
  Metastasis                67.4                                                   71.3                           
  **Lung**                                                                                                        
  No metastasis             83.9            30.528                \<0.001          86.4                  27.412   \<0.001
  Metastasis                60.0                                                   65.3                           
  **Liver**                                                                                                       
  No metastasis             84.4            61.944                \<0.001          87.1                  66.411   \<0.001
  Metastasis                45.3                                                   49.1                           
  **Brain**                                                                                                       
  No metastasis             81.8            12.199                \<0.001          84.7                  15.972   \<0.001
  Metastasis                50.0                                                   50.0                           
  **Distant lymph nodes**                                                                                         
  No metastasis             83.9            30.786                \<0.001          86.8                  35.067   \<0.001
  Metastasis                60.5                                                   63.2                           
                                                                                                                  

OS: Overall Survival; CSS: Cancer Specific Survival.

###### 

Multivariate analyses of OS and CSS according to metastatic organs.

  Variable           OS                    CSS                             
  ------------------ --------------------- --------- --------------------- ---------
  No metastasis      Reference                       Reference             
  Bone metastasis    1.989 (1.487-2.660)   \<0.001   2.081 (1.527-2.838)   \<0.001
  Lung metastasis    1.929 (1.395-2.667)   \<0.001   1.970 (1.395-2.780)   \<0.001
  Liver metastasis   4.008 (2.823-5.690)   \<0.001   4.418 (3.064-6.370)   \<0.001
  Brain metastasis   2.707 (1.341-5.465)   0.005     3.213 (1.583-6.519)   0.001
  DL metastasis      2.178 (1.563-3.036)   \<0.001   2.435 (1.725-3.437)   \<0.001

Adjusted for molecular subtype, age, race, marital status, grade, tumor size, regional lymph node invasion and therapies. OS: Overall Survival; CSS: Cancer Specific Survival; HR: Hazard Ratio.
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